Fasiha Kanwal

SOCIETY: AASLD

SOCIETY: AASLD

BACKGROUND AND AIMS: Screening tools are needed for early detection of NAFLD-fibrosis. We aimed to identify risk factors for NAFLD-fibrosis in the multiethnic population of the U.S. and thus accelerate development of equitable screening tools…

BACKGROUND: With the recent increase in metabolic liver diseases and viral hepatitis on anti-viral agents, risk stratification biomarkers are urgently needed to identify cirrhosis patients who should be prioritized for hepatocellular carcinoma (HCC) screening for early detection…

BACKGROUND. Several inflammatory and metabolic biomarkers have been associated with hepatocellular carcinoma (HCC) risk in phase I and II biomarker studies but not in longitudinal studies…

BACKGROUND: Patients with MASLD and diabetes have an increased risk of cirrhosis and hepatocellular cancer (HCC). Recent studies show that glucagon-like peptide-1 (GLP-1) agonists, such as semaglutide, are effective in improving liver inflammation in MASLD…

BACKGROUND: Current understanding of the rates and trajectories of progression to cirrhosis complications is derived from outdated data. We examined the progression patterns of cirrhosis and their implications, focusing on the different outcomes of prolonged illness _vs_…

ASSOCIATION OF GLUCAGON-LIKE PEPTIDE-1 AGONISTS WITH CIRRHOSIS AND HEPATOCELLULAR CANCER IN METABOLIC DYSFUNCTION ASSOCIATED STEATOTIC LIVER DISEASE (MASLD)